SCHEMBL13180239

SCHEMBL13180239

CCc1cc(NC(=O)NC)ccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
EPHX1 P07099 2/20 0.53
EPHX2 P34913 2/20 0.53
CYP3A4 P08684 1/20 0.50
CA2 P00918 1/20 0.49
CA4 P22748 1/20 0.49
CA5A P35218 1/20 0.49
CA9 Q16790 1/20 0.49
PYGL P06737 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 1/20 0.47
LMNA P02545 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
CHRM1 P11229 1/20 0.47
SLC6A2 P23975 1/20 0.47
PDE4A P27815 1/20 0.47
ADRA1A P35348 1/20 0.47
OPRM1 P35372 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14368008 0.83 RORC (0.58) EPHX1EPHX2CYP3A4HTTPOLB
SCHEMBL30876298 0.82 EPHX1 (0.78) ALDH1A1EPHX1EPHX2CYP3A4CA2
SCHEMBL2893642 0.82 EPHX1 (0.78) ALDH1A1EPHX1EPHX2CYP3A4CA2
SCHEMBL19049142 0.79 ALDH1A1 (0.59) ALDH1A1EPHX1EPHX2CYP3A4CA2
SCHEMBL31453567 0.78 IDO1 (0.51) ALDH1A1EPHX1EPHX2CYP3A4MEN1
SCHEMBL27441962 0.78 ALDH1A1 (0.49) ALDH1A1CYP3A4MEN1KMT2ANPC1
SCHEMBL13180237 0.78 KMT2A (0.50) ALDH1A1PYGLMEN1KMT2ANPC1
SCHEMBL7520700 0.77 MAPT (0.45) ALDH1A1EPHX1EPHX2CYP3A4CA2
SCHEMBL11357914 0.76 ALDH1A1 (0.59) ALDH1A1EPHX1EPHX2CA2CA4
SCHEMBL11755742 0.76 SMN1; SMN2 (0.69) ALDH1A1EPHX1EPHX2CA2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CCR2, CCR9, CCR1 ALDH1A1 1572/4885EPHX1 556/4885EPHX2 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.